Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 51, Issue 1, 2016, Pages 97-106

  Niemantsverdriet, Ellis ^a   Goossens, Joery ^a   Struyfs, Hanne ^a   Martin, Jean Jacques ^a   Goeman, Johan ^b   De Deyn, Peter Paul ^a,b   Vanderstichele, Hugo ^c   Engelborghs, Sebastiaan ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ZNA Hospital Network Antwerp   (Belgium)

^c ADX NEUROSCIENCES   (Belgium)

Author keywords

(pre )analytical variability; Alzheimer's disease; biomarkers; cerebrospinal fluid; diagnostic accuracy; differential dementia diagnosis

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID; CLINICAL CLASSIFICATION; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; COGNITIVE DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; MIDDLE AGED; NONPARAMETRIC TEST; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUTOPSY; COGNITIVE DYSFUNCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 84960154670     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150953     Document Type: Article

References (41)

1. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159
2. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413
3. Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der FlierW, Blennow K,Wolz R, Scheltens P, Visser PJ (2013) Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 80, 1124-1132
4. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234
5. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11, 58-69
6. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K (2005) Simultaneous measurement of betaamyloid( 1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51, 336-345
7. Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM (2012) Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-basedxMAPmultiplex technology for early detection of Alzheimer's disease. Methods 56, 484-493
8. Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S (2013) Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J Alzheimers Dis 33, 117-131
9. Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM (2011) Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68, 1137-1144
10. Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, Teunissen CE (2013) Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimers Dement 9, 276-283
11. Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM(2007) Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem 53, 859-865
12. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleo A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schroder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Kaser SA, Alzheimer's Association QC Program Work Group (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9, 251-261
13. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253
14. Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, Scheltens P, Rikkert MG, Verbeek MM, Teunissen CE (2014) Variability of CSF Alzheimer's disease biomarkers: Implications for clinical practice. PLoS One 9, e100784
15. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA (2010) Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta((1-42)), tau, and phosphorylated tau in Alzheimer's disease: Report of an international workshop. Int J Alzheimers Dis, pii: 635053
16. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121, 597-609
17. Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL, Peoc'h K, Schraen S, Pasquier F, Touchon J, Hugon J, Lehmann S, Gabelle A (2013) Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimers Dement 9, 406-413
18. Le Bastard N, De Deyn PP, Engelborghs S (2015) Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 61, 734-743
19. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Saez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M,Visser PJ,TeunissenC(2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update. Biomark Med 6, 419-430
20. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73
21. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 10, 808-817
22. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
24. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on Aging, Alzheimer's Association (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease:Apractical approach. Acta Neuropathol 123, 1-11
25. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3, 32-35
26. Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Marien P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014) Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: A longitudinal study. J Alzheimers Dis 42, 1239-1250
27. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 13, 614-629
28. http://www.fda.gov/downloads/Drugs/DevelopmentApproval Process/UCM439713.pdf
29. Leitao MJ, Baldeiras I, Herukka SK, Pikkarainen M, Leinonen V, Simonsen AH, Perret-Liaudet A, Fourier A, Quadrio I, Veiga PM, de Oliveira CR (2015) Chasing the effects of pre-analytical confounders-A multicenter study on CSF-AD biomarkers. Front Neurol 6, 153
30. Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetterberg H, Blennow K, Teunissen C, Engelborghs S (2013) Alzheimer disease biomarker testing in cerebrospinal fluid: A method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem 59, 710-712
31. Carrillo MC, BlennowK, Soares H, Lewczuk P, Mattsson N, Oberoi P,UmekR,Vandijck M, Salamone S, BittnerT, Shaw LM, Stephenson D, Bain L, Zetterberg H (2013) Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 9, 137-140
32. Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E (2012) Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: Definitions and approaches with focus on amyloid beta42. Biomark Med 6, 409-417
33. Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, Trojanowski JQ, Shaw LM(2014) Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis 41, 441-451
34. Leinenbach A, Pannee J, Dulffer T, Huber A, Bittner T, Andreasson U, Gobom J, Zetterberg H, Kobold U, Portelius E, Blennow K, IFCC Scientific DivisionWorking Group on CSF proteins (2014) Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 60, 987-994
35. Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, Engelborghs S (2015) Cerebrospinal fluid P-Tau181P: Biomarker for improved differential dementia diagnosis. Front Neurol 6, 138
36. Trojanowski JQ, Hampel H (2011) Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol 95, 491-495
37. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M,Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292
38. Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S (2013) Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36, 759-767
39. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: Validation of two novel assays. J Alzheimers Dis 43, 183-191
40. Bittner T, Zetterberg H, Teunissen C, Ostlund R, Militello M, Andersson U, Hubeek I, Gibsone D, Chu D, Eichelauba U, Heiss P, Kobold U, Leinenbach A, Madin K, Manuilova E, Rabe C, Blennow K (2015) Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. doi: 10.1016/j.jalz.2015.09.009
41. Blennow K, Zetterberg H (2015) The Alzheimer's Association QC program for CSF biomarkers. Round 17 results. Available from: http://neurophys.gu.se/digitalAssets/1525/ 1525893 2015-17-summary.pdf